VIDAZA POWDER FOR SUSPENSION FOR INJECTION 100 MG /VIAL

Manufacturer
BAXTER ONCOLOGY GMBH(GERMANY)

Registraction Number
MAL20101997ACRZ

Content:

• Active Ingredient: 100 mg of azacitidine per vial.
• Inactive Ingredients: Mannitol (100 mg).

• Adults: Treatment of MDS subtypes such as refractory anemia (RA), refractory anemia with ringed sideroblasts (RARS), refractory anemia with excess blasts (RAEB), refractory anemia with excess blasts in transformation (RAEB-T), and chronic myelomonocytic leukemia (CML).
• Pediatrics: Treatment of newly diagnosed JMML in patients aged 1 month and older.

1. Reconstitution: Reconstitute the powder with sterile water for injection to form a suspension.
2. Administration: Administer by subcutaneous injection or intravenous infusion.
3. Dosage: For adults with MDS, the recommended starting dose is 75 mg/m² daily for 7 days. For JMML, follow the specific dosing schedule provided in the prescribing information.
4. Monitoring: Regular monitoring of complete blood counts (CBC) and renal function is necessary.